NUVL - Nuvalent, Inc. Stock Price and Quote

NUVL [NASD]

Index	-	P/E	-	EPS (ttm)	-1.51	Insider Own	5.10%	Shs Outstand	48.41M	Perf Week	-1.08%
Market Cap	1.65B	Forward P/E	-	EPS next Y	-2.60	Insider Trans	25.04%	Shs Float	46.09M	Perf Month	-8.90%
Income	-73.00M	PEG	-	EPS next Q	-0.48	Inst Own	89.20%	Short Float / Ratio	7.07% / 16.55	Perf Quarter	0.22%
Sales	-	P/S	-	EPS this Y	-584.20%	Inst Trans	-1.21%	Short Interest	3.26M	Perf Half Y	71.70%
Book/sh	4.89	P/B	6.12	EPS next Y	-33.30%	ROA	-24.30%	Target Price	43.50	Perf Year	146.55%
Cash/sh	4.37	P/C	6.85	EPS next 5Y	-	ROE	-25.20%	52W Range	7.09 - 40.43	Perf YTD	-0.49%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-26.70%	Beta	-
Dividend %	-	Quick Ratio	18.90	Sales past 5Y	-	Gross Margin	-	52W Low	317.98%	ATR	2.00
Employees	57	Current Ratio	18.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.46	Volatility	7.39% 7.38%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-5.10%	Profit Margin	-	Rel Volume	0.10	Prev Close	29.93
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	197.03K	Price	29.64
Recom	1.80	SMA20	0.55%	SMA50	-1.40%	SMA200	27.92%	Volume	2,230	Change	-0.99%

Jan-18-23

Initiated

Wedbush

Outperform

$39

Jun-24-22

Initiated

BMO Capital Markets

Outperform

$28

Mar-16-23 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire +5.45%
Mar-14-23 05:59PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023 PR Newswire +6.05%
Mar-01-23 06:30AM	Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference PR Newswire
Jan-04-23 06:30AM	Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-02-23 09:40AM	Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year? Zacks
10:15AM	Loading…
Dec-13-22 10:15AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 PR Newswire
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now Insider Monkey
Dec-02-22 08:50AM	Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going Zacks
Nov-17-22 12:00PM	What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now? Zacks
Nov-10-22 06:30AM	Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results PR Newswire
Nov-03-22 08:13PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock PR Newswire -6.04%
Oct-31-22 09:14PM	Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire
07:15AM	Nuvalent Announces Public Offering of Common Stock PR Newswire
Oct-28-22 04:18PM	Nuvalent stock jumps on positive data from cancer drug trial American City Business Journals +60.64%
04:06PM	Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win Investor's Business Daily
11:10AM	Loading…
11:10AM	Why Nuvalent Shares Are Surging 45% Today? Benzinga
12:01AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC PR Newswire
Oct-26-22 06:30AM	Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655 PR Newswire
Oct-23-22 09:26AM	We Think Nuvalent (NASDAQ:NUVL) Can Easily Afford To Drive Business Growth Simply Wall St.
Oct-17-22 06:30AM	Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium PR Newswire +6.99%
Oct-06-22 06:30AM	Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors PR Newswire
Sep-20-22 10:16AM	Nuvalent Has Made a Base Pattern on the Charts TheStreet.com
Sep-07-22 06:30AM	Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates PR Newswire +17.55%
Sep-01-22 06:30AM	Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference PR Newswire
Aug-10-22 06:30AM	Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results PR Newswire +12.35%
Aug-05-22 06:30AM	Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting PR Newswire
Aug-03-22 06:30AM	Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference PR Newswire
Jul-20-22 06:30AM	Nuvalent Announces Leadership Promotions PR Newswire -7.92%
Jul-13-22 06:30AM	Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting PR Newswire +5.39%
Jul-01-22 10:52AM	Nuvalent Has Begun the Bottoming Process TheStreet.com
06:30AM	Loading…
Jun-21-22 06:30AM	Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers PR Newswire +10.18%
Jun-02-22 06:38AM	Nuvalent to Present at the 2022 Jefferies Healthcare Conference PR Newswire
May-16-22 09:10AM	Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation Simply Wall St. -7.50%
May-12-22 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results PR Newswire
Apr-11-22 07:21AM	Nuvalent Highlights New Data Exhibiting Expanded Preclinical Activity Of NVL-520 In ROS1-Driven Cancers Benzinga -6.62%
Apr-08-22 01:15PM	Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 PR Newswire
Apr-07-22 06:30AM	Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference PR Newswire
Mar-31-22 06:30AM	Nuvalent Appoints Anna Protopapas as Chair of Board of Directors PR Newswire
Mar-29-22 06:30AM	Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results PR Newswire +7.49%
Mar-08-22 05:38PM	Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 PR Newswire
Mar-02-22 06:30AM	Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference PR Newswire
Feb-03-22 06:30AM	Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors PR Newswire
Jan-07-22 06:30AM	Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor PR Newswire
Jan-04-22 06:30AM	Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire
Nov-10-21 06:30AM	Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results PR Newswire
Oct-29-21 09:55AM	Here's What Nuvalent, Inc.'s (NASDAQ:NUVL) Shareholder Ownership Structure Looks Like Simply Wall St.
Oct-07-21 09:21AM	New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC PR Newswire -6.53%
Sep-08-21 06:30AM	Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results PR Newswire
Aug-06-21 06:26PM	Translate Bio, Nuvalent See Activist Action Barrons.com -11.19%
Aug-02-21 05:39PM	Nuvalent Announces Closing of Upsized Initial Public Offering PR Newswire +20.05%
Jul-28-21 11:22PM	Nuvalent Announces Pricing of Initial Public Offering PR Newswire

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Miller Deborah Ann	Chief Legal Officer	Mar 15	Option Exercise	6.89	2,000	13,780	2,000	Mar 17 04:38 PM
Miller Deborah Ann	Chief Legal Officer	Mar 15	Sale	28.25	2,000	56,509	0	Mar 17 04:38 PM
Noci Darlene	Chief Development Officer	Mar 01	Option Exercise	1.08	3,000	3,240	3,000	Mar 03 04:35 PM
Noci Darlene	Chief Development Officer	Mar 01	Sale	29.88	3,000	89,646	0	Mar 03 04:35 PM
Miller Deborah Ann	Chief Legal Officer	Feb 15	Option Exercise	6.89	2,000	13,780	2,000	Feb 17 04:19 PM
Miller Deborah Ann	Chief Legal Officer	Feb 15	Sale	29.56	2,000	59,127	0	Feb 17 04:19 PM
Noci Darlene	Chief Development Officer	Feb 02	Option Exercise	1.08	3,000	3,240	3,000	Feb 03 04:45 PM
Noci Darlene	Chief Development Officer	Feb 02	Sale	29.56	3,000	88,667	0	Feb 03 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jan 17	Option Exercise	6.89	2,000	13,780	2,000	Jan 19 04:48 PM
Miller Deborah Ann	Chief Legal Officer	Jan 17	Sale	32.62	2,000	65,242	0	Jan 19 04:48 PM
Shair Matthew	Director	Jan 04	Sale	28.04	18,300	513,106	1,944,698	Jan 06 04:42 PM
Miller Deborah Ann	Chief Legal Officer	Dec 15	Option Exercise	6.89	2,000	13,780	2,000	Dec 16 04:48 PM
Noci Darlene	Chief Development Officer	Dec 15	Option Exercise	1.08	4,200	4,536	4,200	Dec 16 04:46 PM
Noci Darlene	Chief Development Officer	Dec 15	Sale	29.91	4,200	125,635	0	Dec 16 04:46 PM
Miller Deborah Ann	Chief Legal Officer	Dec 15	Sale	29.98	2,000	59,955	0	Dec 16 04:48 PM
Shair Matthew	Director	Dec 07	Sale	31.17	18,300	570,458	1,962,998	Dec 09 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Nov 15	Option Exercise	6.89	2,000	13,780	2,000	Nov 17 04:52 PM
Noci Darlene	Chief Development Officer	Nov 15	Option Exercise	1.08	4,200	4,536	4,200	Nov 17 04:46 PM
Noci Darlene	Chief Development Officer	Nov 15	Sale	31.99	4,200	134,350	0	Nov 17 04:46 PM
Miller Deborah Ann	Chief Legal Officer	Nov 15	Sale	31.91	2,000	63,814	0	Nov 17 04:52 PM
Flynn James E	Director by deputization	Nov 03	Buy	33.50	650,000	21,775,000	650,000	Nov 07 06:24 PM
Hack Andrew A. F.	Director	Nov 03	Buy	33.50	149,253	4,999,976	3,577,267	Nov 03 04:15 PM
Shair Matthew	Director	Nov 03	Sale	29.60	37,939	1,123,115	1,981,298	Nov 04 04:45 PM
Shair Matthew	Director	Nov 02	Sale	32.04	95,455	3,058,337	2,019,237	Nov 04 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Oct 28	Option Exercise	6.89	8,968	61,790	8,968	Nov 01 05:23 PM
Noci Darlene	Chief Development Officer	Oct 28	Option Exercise	1.08	1,000	1,080	1,000	Nov 01 05:24 PM
Miller Deborah Ann	Chief Legal Officer	Oct 28	Sale	38.86	8,968	348,470	0	Nov 01 05:23 PM
Noci Darlene	Chief Development Officer	Oct 28	Sale	40.25	1,000	40,250	0	Nov 01 05:24 PM
Noci Darlene	Chief Development Officer	Oct 14	Option Exercise	1.08	4,200	4,536	4,200	Oct 14 04:48 PM
Noci Darlene	Chief Development Officer	Oct 14	Sale	21.41	4,200	89,922	0	Oct 14 04:48 PM
Shair Matthew	Director	Oct 07	Sale	18.70	12,613	235,825	2,114,692	Oct 07 04:52 PM
Shair Matthew	Director	Oct 06	Sale	19.00	8,608	163,552	2,127,305	Oct 07 04:52 PM
Shair Matthew	Director	Oct 05	Sale	19.22	7,884	151,530	2,135,913	Oct 07 04:52 PM
Noci Darlene	Chief Development Officer	Sep 15	Option Exercise	1.08	4,200	4,536	4,200	Sep 16 04:45 PM
Shair Matthew	Director	Sep 15	Sale	18.34	5,650	103,621	2,143,797	Sep 16 04:48 PM
Noci Darlene	Chief Development Officer	Sep 15	Sale	18.14	4,200	76,188	0	Sep 16 04:45 PM
Shair Matthew	Director	Sep 14	Sale	18.36	13,151	241,452	2,149,447	Sep 16 04:48 PM
Noci Darlene	Chief Development Officer	Aug 24	Option Exercise	1.08	1,604	1,732	1,604	Aug 25 04:15 PM
Noci Darlene	Chief Development Officer	Aug 24	Sale	17.03	1,604	27,316	0	Aug 25 04:15 PM
Noci Darlene	Chief Development Officer	Aug 15	Option Exercise	1.08	2,596	2,804	2,596	Aug 17 04:17 PM
Noci Darlene	Chief Development Officer	Aug 15	Sale	17.02	2,596	44,184	0	Aug 17 04:17 PM
Noci Darlene	Chief Development Officer	Jul 19	Option Exercise	1.08	318	343	318	Jul 19 05:01 PM
Noci Darlene	Chief Development Officer	Jul 19	Sale	17.02	318	5,412	0	Jul 19 05:01 PM
Noci Darlene	Chief Development Officer	Jul 18	Option Exercise	1.08	100	108	100	Jul 19 05:01 PM
Noci Darlene	Chief Development Officer	Jul 18	Sale	17.07	100	1,707	0	Jul 19 05:01 PM
Noci Darlene	Chief Development Officer	Jul 15	Option Exercise	1.08	3,782	4,085	3,782	Jul 19 05:01 PM
Noci Darlene	Chief Development Officer	Jul 15	Sale	17.29	3,782	65,379	0	Jul 19 05:01 PM
Shair Matthew	Director	Jul 15	Sale	18.29	2,000	36,580	2,162,598	Jul 15 04:51 PM
Shair Matthew	Director	Jul 13	Sale	18.25	100	1,825	2,164,598	Jul 15 04:51 PM
Noci Darlene	See Remarks	Jul 07	Option Exercise	1.08	16,800	18,144	16,800	Jul 08 04:17 PM
Noci Darlene	See Remarks	Jul 07	Sale	17.61	16,800	295,848	0	Jul 08 04:17 PM
Turner Christopher Durant	Chief Medical Officer	May 17	Option Exercise	6.89	14,513	99,995	14,513	May 19 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience